Thursday, 15 September 2022

Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine

Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine
Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine

Pfizer Inc announced that the first participants have been dosed in a pivotal Phase 3 clinical trial to evaluate the efficacy, safety, tolerability and immunogenicity of the company’s quadrivalent modified RNA (modRNA) influenza vaccine candidate in approximately 25,000 healthy U.S. adults.

Pradip Mahajan Thu, 09/15/2022 - 14:46

source https://www.pharmatutor.org/pharma-news/2022/pfizer-initiates-phase-3-study-of-mrna-based-influenza-vaccine

No comments:

Post a Comment

Pharma openings

  Opportunity for M.Pharm, Msc or PhD as Scientist at PGIMER M.Pharmacy or M.Sc 6 Year of Research Experience or PhD with 3 year of Experien...